229 related articles for article (PubMed ID: 3298786)
1. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J
J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
[TBL] [Abstract][Full Text] [Related]
3. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of the ras oncogene expression in human breast lesions.
Agnantis NJ; Petraki C; Markoulatos P; Spandidos DA
Anticancer Res; 1986; 6(5):1157-60. PubMed ID: 3541779
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes.
Pechoux C; Chardonnet Y; Chignol MC; Noël P
Histol Histopathol; 1994 Jan; 9(1):35-44. PubMed ID: 8003818
[TBL] [Abstract][Full Text] [Related]
6. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis.
Tahara E; Yasui W; Taniyama K; Ochiai A; Yamamoto T; Nakajo S; Yamamoto M
Jpn J Cancer Res; 1986 Jun; 77(6):517-22. PubMed ID: 3089984
[TBL] [Abstract][Full Text] [Related]
7. ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues.
Thor A; Ohuchi N; Hand PH; Callahan R; Weeks MO; Theillet C; Lidereau R; Escot C; Page DL; Vilasi V
Lab Invest; 1986 Dec; 55(6):603-15. PubMed ID: 2431221
[No Abstract] [Full Text] [Related]
8. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
9. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA
Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485
[TBL] [Abstract][Full Text] [Related]
10. Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products.
Caruso A; Schlom J; Vilasi V; Weeks MO; Hand PH
Int J Cancer; 1986 Oct; 38(4):587-95. PubMed ID: 3489681
[TBL] [Abstract][Full Text] [Related]
11. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer.
Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK
Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023
[TBL] [Abstract][Full Text] [Related]
12. Expression of p21 ras oncoproteins in human cancers.
Tanaka T; Slamon DJ; Battifora H; Cline MJ
Cancer Res; 1986 Mar; 46(3):1465-70. PubMed ID: 3510727
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans.
Ward JM; Perantoni AO; Santos E
Oncogene; 1989 Feb; 4(2):203-13. PubMed ID: 2648257
[TBL] [Abstract][Full Text] [Related]
14. Detection of c-ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis.
Tsuda T; Mochizuki M; Wakasa H
J Gastroenterol; 1995 Nov; 30 Suppl 8():30-2. PubMed ID: 8563883
[TBL] [Abstract][Full Text] [Related]
15. Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on ras-p21 function during promotion and progression stages of colon cancer.
Singh J; Hamid R; Reddy BS
Cancer Res; 1997 Jan; 57(2):253-8. PubMed ID: 9000564
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical study of ras p21 expression in human gastric cancers and benign lesions].
Nakajima K
Hokkaido Igaku Zasshi; 1987 Jul; 62(4):573-80. PubMed ID: 3315926
[TBL] [Abstract][Full Text] [Related]
17. Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas.
Theillet C; Lidereau R; Escot C; Hutzell P; Brunet M; Gest J; Schlom J; Callahan R
Cancer Res; 1986 Sep; 46(9):4776-81. PubMed ID: 3524819
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas.
Magrisso IJ; Richmond RE; Carter JH; Pross CB; Gilfillen RA; Carter HW
Lab Invest; 1993 Dec; 69(6):674-81. PubMed ID: 8264230
[TBL] [Abstract][Full Text] [Related]
19. Optimal preservation of p21 ras immunoreactivity and morphology in paraffin-embedded tissue.
Going JJ; Williams AR; Wyllie AH; Anderson TJ; Piris J
J Pathol; 1988 Jul; 155(3):185-90. PubMed ID: 3045276
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
Kumar S; Hand PH; Marsden HB; Kumar P; Thor A
Anticancer Res; 1991; 11(4):1657-62. PubMed ID: 1660693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
